Medidata Solutions’ (MDSO) Buy Rating Reaffirmed at SunTrust Banks, Inc.

SunTrust Banks, Inc. reissued their buy rating on shares of Medidata Solutions, Inc. (NASDAQ:MDSO) in a research report released on Friday, October 27th. SunTrust Banks, Inc. currently has a $92.00 price target on the stock.

A number of other analysts have also commented on MDSO. Piper Jaffray Companies boosted their price objective on Medidata Solutions to $87.00 and gave the stock an overweight rating in a report on Friday, July 7th. Citigroup Inc. reissued a buy rating and set a $94.00 price objective (up from $77.00) on shares of Medidata Solutions in a report on Monday, July 10th. J P Morgan Chase & Co boosted their target price on Medidata Solutions to $87.00 and gave the stock an overweight rating in a research note on Tuesday, July 18th. Morgan Stanley boosted their target price on Medidata Solutions from $74.00 to $86.00 and gave the stock an overweight rating in a research note on Thursday, July 20th. Finally, Needham & Company LLC restated a buy rating and issued a $90.00 target price (up previously from $75.00) on shares of Medidata Solutions in a research note on Friday, July 21st. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Medidata Solutions has an average rating of Buy and an average target price of $83.54.

Medidata Solutions (NASDAQ:MDSO) opened at $66.95 on Friday. The company has a market capitalization of $3,840.30, a PE ratio of 79.14, a price-to-earnings-growth ratio of 3.95 and a beta of 1.78. Medidata Solutions has a twelve month low of $47.77 and a twelve month high of $85.92. The company has a current ratio of 1.29, a quick ratio of 3.37 and a debt-to-equity ratio of 0.61.

Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Thursday, October 26th. The company reported $0.33 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.02. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The business had revenue of $140.08 million during the quarter, compared to analyst estimates of $141.27 million. During the same period in the previous year, the company posted $0.28 EPS. The firm’s revenue was up 16.7% compared to the same quarter last year. equities analysts anticipate that Medidata Solutions will post 0.77 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Medidata Solutions’ (MDSO) Buy Rating Reaffirmed at SunTrust Banks, Inc.” was reported by Week Herald and is owned by of Week Herald. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://weekherald.com/2017/11/15/medidata-solutions-mdso-buy-rating-reiterated-at-suntrust-banks-inc.html.

In related news, Director Robert Taylor sold 5,000 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $71.39, for a total value of $356,950.00. Following the transaction, the director now owns 49,372 shares of the company’s stock, valued at $3,524,667.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael I. Otner sold 10,000 shares of the stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $70.88, for a total value of $708,800.00. Following the completion of the transaction, the executive vice president now directly owns 80,674 shares in the company, valued at approximately $5,718,173.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 215,000 shares of company stock worth $14,817,750. Insiders own 5.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of MDSO. UBS Asset Management Americas Inc. boosted its position in Medidata Solutions by 16.7% during the first quarter. UBS Asset Management Americas Inc. now owns 29,724 shares of the company’s stock valued at $1,715,000 after buying an additional 4,251 shares during the period. OppenheimerFunds Inc. boosted its position in Medidata Solutions by 28.4% during the first quarter. OppenheimerFunds Inc. now owns 6,863 shares of the company’s stock valued at $396,000 after buying an additional 1,517 shares during the period. Teachers Advisors LLC boosted its position in Medidata Solutions by 254.0% during the first quarter. Teachers Advisors LLC now owns 371,554 shares of the company’s stock valued at $21,435,000 after buying an additional 266,606 shares during the period. Thrivent Financial For Lutherans boosted its position in Medidata Solutions by 5.2% during the first quarter. Thrivent Financial For Lutherans now owns 31,000 shares of the company’s stock valued at $1,788,000 after buying an additional 1,520 shares during the period. Finally, Vanguard Group Inc. boosted its position in Medidata Solutions by 5.1% during the first quarter. Vanguard Group Inc. now owns 4,874,974 shares of the company’s stock valued at $281,237,000 after buying an additional 235,190 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply